PMID- 30643432
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220331
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Comparison of the diagnostic performance of fluorescence in situ hybridization 
      (FISH), nuclear matrix protein 22 (NMP22), and their combination model in bladder 
      carcinoma detection: a systematic review and meta-analysis.
PG  - 349-358
LID - 10.2147/OTT.S186065 [doi]
AB  - BACKGROUND: Emerging studies reported that combination of fluorescence in situ 
      hybridization (FISH) and nuclear matrix protein 22 (NMP22) could increase the 
      sensitivity and specificity of bladder carcinoma (BC) management. Nevertheless, 
      the reports remain inconsistent. This meta-analysis was undertaken to evaluate 
      the diagnostic performance of FISH, NMP22, and their combination model in BC. 
      MATERIALS AND METHODS: A systematic literature search was carried out in PubMed, 
      Embase, Cochrane Library, Web of Science, Chinese National Knowledge 
      Infrastructure, and Wanfang database dated up to October 2018. Suitable studies 
      were identified and raw data were extracted. Meta-analysis was conducted to 
      calculate the global sensitivities, specificities, likelihood ratio, diagnostic 
      odds ratio (DOR), and the areas under the summary receiver operating 
      characteristic (SROC) curves for FISH, NMP22, and their combination model, 
      separately. All the meta-analysis estimates were derived using STATA (version 
      12.0) and MetaDisc (version 1.4) software packages. RESULTS: Seven eligible 
      studies were included for analysis. The global sensitivities with 95% CI for 
      FISH, NMP22, and their combination model were 0.79 (95% CI: 0.75-0.83), 0.76 (95% 
      CI: 0.71-0.81), and 0.82 (95% CI: 0.75-0.88); specificities were 0.85 (95% CI: 
      0.76-0.91), 0.70 (95% CI: 0.55-0.81), and 0.90 (95% CI: 0.70-0.97); DORs were 
      22.215 (95% CI: 10.695-46.144), 7.365 (95% CI: 3.986-13.610), and 41.940 (95% CI: 
      13.546-129.853); and the areas under the SROC curves were 0.86 (95% CI: 
      0.82-0.88), 0.79 (95% CI: 0.76-0.83), and 0.90 (95% CI: 0.87-0.92). CONCLUSION: 
      Our systematic review implied that the diagnostic performance of combination 
      model of FISH plus NMP22 may outperform FISH or NMP22 alone in BC detection.
FAU - Liang, Qindong
AU  - Liang Q
AD  - Department of Clinical Laboratory, Affiliated Hospital & Clinical Medical College 
      of Chengdu University, Chengdu, Sichuan, China, shengshangchun@126.com.
FAU - Zhang, Guangjie
AU  - Zhang G
AD  - Department of Clinical Laboratory, Chengdu Fifth People's Hospital, Chengdu, 
      Sichuan, China.
FAU - Li, Wuxian
AU  - Li W
AD  - Department of Clinical Laboratory, Chongqing Health Center for Women and 
      Children, Chongqing, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Blood Transfusion, The First Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Sheng, Shangchun
AU  - Sheng S
AD  - Department of Clinical Laboratory, Affiliated Hospital & Clinical Medical College 
      of Chengdu University, Chengdu, Sichuan, China, shengshangchun@126.com.
LA  - eng
PT  - Journal Article
DEP - 20181231
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6317485
OTO - NOTNLM
OT  - bladder cancer
OT  - diagnosis
OT  - fluorescence in situ hybridization
OT  - meta-analysis
OT  - nuclear matrix protein 22
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2019/01/16 06:00
MHDA- 2019/01/16 06:01
PMCR- 2018/12/31
CRDT- 2019/01/16 06:00
PHST- 2019/01/16 06:00 [entrez]
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2019/01/16 06:01 [medline]
PHST- 2018/12/31 00:00 [pmc-release]
AID - ott-12-349 [pii]
AID - 10.2147/OTT.S186065 [doi]
PST - epublish
SO  - Onco Targets Ther. 2018 Dec 31;12:349-358. doi: 10.2147/OTT.S186065. eCollection 
      2019.